Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.youtube.com/user/AndesGold
Interesting and informative. AGCZ
The President & CEO of the Company's operating subsidiary, Mr. David Cade, said, "This new phase of patent filings provides continuing meaningful patent protection for the Company and its shareholders. Based on the opinion of our highly esteemed patent counsel, this novel technology does not infringe on any known prior art as reflected in issued and unexpired patents."
AFPW has the only technology for their product and the other company has competition.
What trial?
You're kind - but I tend to think he said what he meant and it was certainly directed to my one post. Thanks anyway.
I post one time in four weeks and you say I see the hyper Queen is back????? Is this board for "guys" only?
GENTA (GNTA)Tesetaxel is the leading oral taxane in clinical development. The trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY, in collaboration with three other U.S. centers.
"These data confirm results from our prior study, both of which show substantial activity for tesetaxel in patients with advanced, HER2-negative breast cancer", said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development, and Chief Medical Officer. "Genta is also exploring an alternate dosing schedule in this population using weekly treatment. Based on this favorable experience, and after conferring with regulatory authorities in the U.S. and EU, Genta plans to proceed with a new randomized trial of tesetaxel as initial, single-agent chemotherapy for patients with recurrent breast cancer."
Genta Incorporated (GNTA) announced results from the Company's Phase 2, confirmatory, clinical trial of tesetaxel as 2nd-line treatment of patients with advanced gastric cancer. The trial was conducted at M.D. Anderson Cancer Center, Houston, TX, in collaboration with Northwestern University, Chicago, IL, the University of Pennsylvania, Philadelphia, PA, and the Severance Hospital, Seoul, Korea.
"With this study, Genta has completed an extensive Phase 2 evaluation of tesetaxel as 2nd-line treatment in a total of 88 patients with advanced gastric cancer," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development, and Chief Medical Officer. "Our data confirm the activity of tesetaxel in gastric cancer at a level that is at least equivalent to docetaxel, but with an improved safety profile. Results from this new study support projections for overall survival in our randomized trial. We look forward to accelerating recruitment to this new multinational study."
Unlike standard taxanes that must be administered intravenously, tesetaxel is a capsule that is taken by mouth. Compared with the standard agents, clinical and preclinical data show that tesetaxel:
Is active in diseases that are resistant to standard taxanes
Is not associated with serious (occasionally fatal) hypersensitivity reactions
Eliminates requirements for premedication (e.g., steroids, antihistamines, etc.)
Reduces damage to peripheral nerves
Offers flexible and convenient dosing for patients
Thus, tesetaxel offers substantial opportunities to improve patient convenience, safety, and anticancer activity.
Genta is conducting a multinational, randomized, double-blind trial that compares capecitabine with tesetaxel or placebo in patients with 2nd-line gastric cancer.
I can PM the ticker if you want to see it.
No, nothing with government.
Another hydrogen tech stock went over a penny yesterday. That's up over 500% since Jan.
Default" simply means that they are late filling their Annual List of Officers with the Secretary of State.
To emerge from a "Default" status, all the corporation must do is pay a $75 late fee, and file the Annual List as Usual.
That is the only penalty, and only amounts to a "Late Fee".
The company has a right to transact business for one year while being in "Default". It still legally exists. It merely owes a late fee.
If the corporation remains in default for 12 months, then it's corporate charter is revoked, and its ability to transact business is forfeited.
Until that time, however, they still have the right to transact business.
If at any time they pay the $75 late free (which can be done online), pay $125 to file their Annual List Of Officers (which can be one person), they will no longer be in default
If they are in CA, Then who runs NBI in FL. The only time I called NBI DeZanger was there. Been a few months but I talked to him.
What does that have to do with the last trade? If you just need to vent, that's fine but I didn't make that trade and I may have more invested in CBIS than most on this board.
LOL - I wouldn't think of it. I still think you should go visit Dezanger and get us some answers. Maybe you could catch him at home by surprise. Probably the only way to catch him, don't you think?
That last trade just shows how bad shorts want to take CBIS down. GO DR BOB and CBIS
Curing Cancer and a multitude of other diseases - GO DR BOB and CBIS
CBIS is surrounding themselves with companies and people in the right places to make big things happen. If you can comprehend the direction they are taking us. CBIS is very transparent with updating all their dealings. Isn't that what we all want? GO DR BOB and CBIS
AGCZ - Share Structure
Market Value $49,937,435 a/o Mar 23, 2012
Shares Outstanding 1,019,131,318 a/o Feb 22, 2012
Float 117,428,968 a/o Feb 22, 2012
Authorized Shares 1,500,000,000 a/o Sep 30, 2011
EGTK isn't getting the attention of big investors yet. Revenue is just starting but with the new contracts we will soon see the huge gains you are talking about. EGTK
CALVF - Profits for last year. Blanket's unaudited revenues and profit after tax for the year to December 31, 2011 were US$56.6 million and US$19.2 million respectively.
Caledonia Mining Corporation ("Caledonia" or the "Company") (TSX: CAL)(OTCQX: CALVF)(AIM: CMCL) is pleased to announce the signing of an agreement with the National Indigenisation and Economic Empowerment Fund ("NIEEF") to transfer 16% of the Blanket Mine in Zimbabwe ("Blanket") and the receipt of the Certificate of Compliance with requirements of Section 31(1)(a) of the Zimbabwe Indigenisation Act.
A conditional agreement has been signed for the sale of 16% of Blanket for a consideration of US$11.742 million to NIEEF. This agreement is in accordance with the Memorandum of Understanding ("MoU"), which was signed with the Government of Zimbabwe on February 20, 2012 pursuant to which Indigenous Zimbabweans will acquire 51% ownership of the Blanket Mine for a paid transactional value of US$30.09 million.
This agreement is in addition to the following conditional agreements which have already been signed in accordance with the terms of the MoU and as disclosed in previous news releases:
View data
-- an agreement for the sale of 15% of Blanket to a consortium of Indigenous Zimbabweans for a consideration of US$11.008 million; -- an agreement for the sale of 10% of Blanket to The Blanket Mine Employee Trust that has been established for the benefit of the present and future managers and employees of Blanket for a consideration of US$7.339 million; and -- an agreement for the donation of 10% of Blanket to the Gwanda Community Share Ownership Trust that has been established for the benefit of the local community. Pursuant to the terms of the MoU, Blanket will also make a non-refundable donation of US$1.0 million to this trust.
Caledonia will facilitate the vendor funding of the sale transactions which will be repaid from future Blanket dividends attributable to the Indigenous Zimbabwean shareholders. Outstanding balances on these facilitation loans will attract interest at a rate of 10% over the 12-month LIBOR. The timing for the repayment of the facilitation loans will depend on the future financial performance of Blanket. Caledonia expects to redeploy the proceeds received in its projects.
Completion of these agreements is subject to several conditions precedent, which include certain approvals from the Reserve Bank of Zimbabwe which are expected to be met in the near future.
Blanket's unaudited revenues and profit after tax for the year to December 31, 2011 were US$56.6 million and US$19.2 million respectively.
View data
Contacts: Caledonia Mining Corporation Mark Learmonth + 27 11 447 2499 marklearmonth@caledoniamining.com Canaccord Genuity Limited John Prior / Sebastian Jones + 44 20 7523 8350 Newgate Threadneedle Beth Harris / Josh Royston + 44 20 7653 9850 CHF Investor Relations Stephanie Fitzgerald + 1 416 868 1079 x 222 stephanie@chfir.com
SOURCE: Caledonia Mining Corporation
mailto:marklearmonth@caledoniamining.com
mailto:stephanie@chfir.com
CALVF NEWS doesn't transfer to this site. I wonder why. Can you do something about it? TIA
CALVF -NEWS - Caledonia Concludes Sale Agreement With National Indigenisation And Economic Empowerment Fund And Receives Indigenisation Compliance Certificate
CALVF -NEWS - Caledonia Concludes Sale Agreement With National Indigenisation And Economic Empowerment Fund And Receives Indigenisation Compliance Certificate
CALVF -NEWS - Caledonia Concludes Sale Agreement With National Indigenisation And Economic Empowerment Fund And Receives Indigenisation Compliance Certificate
That's what I said - reverse merger. You can change the ticker without audited financials. At least I'm in another company that changed the ticker a few months back and we are still waiting for the audits.
It's just a way to bring a private company public. The stock is traded under MILV ticker but the business NBI. I think the company will eventually apply to change the ticker but that takes approval by finra.
Florida Department of State - Division of Corporations www.sunbiz.org Florida State Flag
Detail by Entity Name
Florida Profit Corporation
NATURE'S BIOCEUTICALS, INC.
Filing Information
Document Number P08000000023
FEI/EIN Number 264509161
Date Filed 12/31/2007
State FL
Status ACTIVE
Effective Date 12/29/2007
Last Event REINSTATEMENT
Event Date Filed 10/24/2011
Event Effective Date NONE
Principal Address
1616-102 W. CAPE CORAL PKWY
# 135
CAPE CORAL FL 33914 US
Changed 10/24/2011
Mailing Address
1616-102 W. CAPE CORAL PKWY
# 135
CAPE CORAL FL 33914 US
Changed 10/24/2011
Registered Agent Name & Address
DEZANGER, ROBERT A III
1616-102 W. CAPE CORAL PKWY
# 135
CAPE CORAL FL 33914 US
Address Changed: 10/24/2011
Officer/Director Detail
Name & Address
Title P
DEZANGER, ROBERT A III
1616-102 W. CAPE CORAL PKWY # 135
CAPE CORAL FL 33914 US
Title S
ZUCK, LISA M
1616-102 W. CAPE CORAL PKWY # 135
CAPE CORAL FL 33914 US
Title CFO
WEINER, RICHARD C
1616-102 W. CAPE CORAL PKWY # 135
CAPE CORAL FL 33914 US
Annual Reports
Report Year Filed Date
2010 02/16/2010
2011 10/24/2011
2012 02/14/2012
Document Images
02/14/2012 -- ANNUAL REPORT
10/24/2011 -- REINSTATEMENT
02/19/2010 -- Off/Dir Resignation
02/16/2010 -- ANNUAL REPORT
08/20/2009 -- Reg. Agent Change
03/19/2009 -- REINSTATEMENT
12/31/2007 -- Domestic Profit
NBI (Nature's Bioceuticals is a corporation filed with the SOS of Florida where they do business. The filing is up to date. No wonder Jason was confused when you ask that question. Through the reverse merger NBI owns MILV.
Good time to load today. This is huge. That update in not hard to read at all. LOL CBIS
EGTK - NEWS - The 10-year contract is expected to yield revenues of approximately $30,000,000 in the first three years of full operations, with expected total revenues of about $100,000,000.
EGTK - NEWS The 10-year contract is expected to yield revenues of approximately $30,000,000 in the first three years of full operations, with expected total revenues of about $100,000,000.
EGTK NEWS - Best part! In Bosnia-Herzegovina, we are implementing our largest commercial project, supplying significant ongoing quantities of natural gas to two industrial consumers-including Aluminij d.o.o. Mostar - one of Eastern Europe's largest aluminum producing factories-as part of a multi-million dollar natural gas supply contract signed during 2011.The 10-year contract is expected to yield revenues of approximately $30,000,000 in the first three years of full operations, with expected total revenues of about $100,000,000.
Nature’s Bioceuticals is soon to release the Nature’s Bioceuticals Kidney Tonic. This breakthrough product contains only three herbs yet is powerful in maintaining the kidney filtration function and also aides in the reliving discomfort from uneven urinary flow. In addition, men with enlarged prostates whom have taken Nature’s Bioceuticals Kidney Tonic have reported a reduction of their prostates to normal levels. The formula has slight diuretic properties and may also increase the urine stream of those suffering with a slow stream.
Chronic kidney disease (CKD) is a growing health problem in the United States. A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease. Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion. The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion. The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.
BERKELEY HEIGHTS, NJ – June 18, 2012– Genta Incorporated (GNTA) announced that the Company’s Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and status update of recent research at the Business Forum during the BIO International Convention on Wednesday, June 20, 2012, at 8:30 AM EDT.
The conference will be held at The Boston Convention and Exhibition Center, Boston, MA. Further information about the 2012 BIO International Business Forum is available at: http://convention.bio.org/businessforum/.
WEIGHT LOSS FORMULA - Coming Soon
According to current government data, 66 percent of the 229.5 million American adults are overweight (BMI of 25-29.9) and nearly 31 percent of those people are obese (BMI of 30 or higher).* Those people whom are overweight are in greater danger of developing obesity-related health complications such as heart attacks and diabetes. The population of Americans whom are not overweight are often concerned with maintaining his/her weight for both health and cosmetic reasons. A number of supervised weight loss programs exist, however, few consist of only all-natural supplements. Nature’s Bioceuticals Weight Loss Formula will provide health care providers and consumers with an herbal product that is easy to consume and produces results with little side effects common to non-natural products.
Nature’s Bioceuticals Weight Loss Formula contains a proprietary blend of 12 natural herbs that have shown to assist people in reaching their weight loss goals. The formula curbs the appetite and speeds up metabolism without causing the usual jittery feeling associated with most weight loss products. People who take Nature’s Bioceuticals Weight Loss Formula do not notice a change in the way they feel; people are simple less hungry, therefore they lose unwanted pounds. MILV
Sinus Support Formula
Those who have used Nature’s Bioceuticals Sinus Formula have found that sinus issues and associated symptoms are usually alleviated within two days; the formula stops a runny nose or loosens up a stuffy nose; and the product also works well for allergy/hay fever and cold symptoms.
Nature’s Bioceuticals Sinus Formula consists of a combination of herbs blended in a solution made of angstrom silver, an all natural liquid known to many as nature’s first antibiotic. Those who have used Nature’s Bioceuticals Sinus Formula have found that sinus problems and associated symptoms are usually alleviated within two days; the formula stops a runny nose or loosens up a stuffy nose; and the product also works well for allergy/hay fever and cold symptoms.
Facts about Sinuses
Sinuses are empty cavities within the cheek bones, around the eyes and behind the nose whose purpose is to warm, moisten and filter air in the nasal cavity. Sinusitis, or a sinus infection, is the inflammation or swelling of one or more of the nasal sinuses and nasal passages.
Symptoms of sinusitis include pressure around the nose, eyes or forehead; a stuffy nose; thick, discolored nasal drainage; bad-tasting post-nasal drip; cough; head congestion; ear fullness; and a headache. Symptoms may also include a toothache, tiredness and, occasionally, a fever.
Anything that causes a swelling in the nose - an infection, allergic reaction, or an inflammatory reaction to a chemical to which you may get exposed - can affect your sinuses. Allergies, or "hay fever," put you at risk for developing sinusitis because allergies can cause swelling of the sinuses and nasal mucous linings. This swelling prevents the sinus cavities from draining, and increases your chances of developing secondary bacterial sinusitis. Air trapped within a blocked sinus, along with pus or other secretions may cause pressure on the sinus wall that can cause the intense pain of a sinus attack. Similarly, when air is prevented from entering a paranasal sinus by a swollen membrane at the opening, a vacuum can be created that also causes pain.
Health experts usually divide sinusitis cases into Acute, which last up to 4 weeks; Subacute, which last 4 to 12 weeks; Chronic, which last more than 12 weeks but may continue for months or even years; and Recurrent, with several acute attacks within a year. While sinus problems are not something that most people think about as a major medical problem, sinusitis is an incredible concern to many people each year. Whether caused by a cold, infection or allergy,
Nature’s Bioceuticals Sinus Formula can provide much needed relief from sinus pressure and discomfort.
Ingredients:
Ionic Silver Solution 100 ppm
Oregano Oil
Peppermint Oil
Eucalyptus Flobulus Oil
New products coming soon - Kidney Formula
Nature’s Bioceuticals Breathing Relief Formula
People who have chronic breathing disorders, or anyone who has ever experienced the discomfort of choking on a piece of food, know the horror of not being able to properly breathe. Nature’s Bioceuticals Breathing Formula is an all natural product that assists in providing relief and relaxation from the lack of breath in just minutes. In addition, when taken over a longer period of time, the product promotes healthier lungs, improved breathing, and a better exchange of clean air.
According to the American Lung Association, there are currently 35 million people with chronic breathing disorders in the United States. This includes such disorders as chronic bronchitis, asthma and emphysema, as well as lung disease, the third largest cause of death in the country.
With such a vast market for products to assist in combating chronic breathing disorders, few natural products are available to those who suffer with these ailments, and so research has shown that nearly 40 percent of that population is actively seeking alternative treatments.
Nature’s Bioceuticals Breathing Formula is not only easy to take in its liquid formula, but the blend of herbs and tree barks promotes healthy breathing function to people with shortness of breath in an all natural formula.
Nature’s Bioceuticals Breathing Formula consists of a unique blend of herbs and tree barks. This combination of natural ingredients, liquefied in a water base, has been shown to relax and dilate the bronchial tubes. The Breathing Formula also contains mild expectorants help to expel the blockage from the bronchial tubes and lungs, as well as natural antibiotics that increase effectiveness.
When taken during a bout of loss of breath, Nature’s Bioceuticals Breathing Relief Formula may help to provide relief almost immediately while use over a longer term provides a deep cleansing and rejuvenation of the lungs, promoting a better exchange of air.